KetoProPig 100mg/ml Oral Solution for Pigs

Main information

  • Trade name:
  • KetoProPig 100mg/ml Oral Solution for Pigs
  • Pharmaceutical form:
  • Oral solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • KetoProPig 100mg/ml Oral Solution for Pigs
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ketoprofen
  • Therapeutic area:
  • Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0239/001
  • Authorization date:
  • 10-07-2011
  • EU code:
  • UK/V/0239/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:November2011

AN:01317/2011

Page1of8

SUMMARYOFTHEPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

KetoProPig100mg/mlOralSolutionforuseindrinkingwaterforPigs

KeProPig100mg/mlOralSolutionforuseindrinkingwaterforPigs(ESand

PO)

2. QUALITATIVEANDQUANITIATIVECOMPOSITION

Eachmlcontains:

Activesubstance

Ketoprofen: 100mg

Excipients

BenzylAlcohol: 20mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Oralsolution

Transparentandcolourlessliquid.

4. CLINICALPARTICULARS

4.1 Targetspecies

FatteningPigs

4.2 IndicationsforUse

Symptomatictreatmentforreductionofpyrexiaincasesofacuteinfectious

respiratorydiseaseinfatteningpigsincombinationwithanappropriateanti-

infectivetherapy.

4.3 Contra-Indications

Donotuseincaseofhypersensitivitytoketoprofen.

Donotuseinanimalsknowntobeallergictoaspirin.

Donotuseinpregnantanimals.

Donotuseinpigsalreadysufferingfromgastriculcers,inordernottoaggravate

theirsituation.

Revised:November2011

AN:01317/2011

Page2of8

Revised:November2011

AN:01317/2011

Page3of8

4.4 Specialwarningsforeachtargetspecies

Avoiduseindehydrated,hypovolaemicorhypotensivepigsasthereisa

potentialriskofincreasedrenaltoxicity.

Useinveryyounganimalsmayinvolveadditionalrisk:however,ifused,

animalsrequirecarefulclinicalmanagement.

Asketoprofenisulcerogenic,theuseisnotrecommendedincaseofPMWS

(Post-weaningmultisystemicwastingsyndrome)becauseulcersarealready

frequentlyassociatedwiththispathology.

Donotexceedtherecommendeddosetoreducetheriskofadversereactions.

Tolimittheappearanceofulcers,administrationovera24hourperiodis

recommended.

Forsafetyreasonstheadministrationoftheproductmustnotexceeda

maximumtreatmentperiodofthreedays.

4.5 SpecialPrecautionsforUse

i. Specialprecautionsforuseinanimals

Donotuseinpigssufferingfromcardiac,hepaticorrenaldiseaseor

gastrointestinalproblems,wherethereisthepossibilityofgastro-

intestinalulcerationorbleedingorwherethereisevidenceofablood

dyscrasia.

Donotuseincaseofhypersensitivitytoketoprofenortoanyofthe

excipients.

Donotuseinanimalsknowntobeallergictoaspirin.

Ifseriousadverseeventssuchassignsofulcersorgastrointestinal

haemorrhageoccur,useoftheproductshouldbestoppedandthe

adviceofaveterinarianshouldbesought.

ii. Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttotheanimals

-Personalprotectiveequipmentconsistingofrubberglovesand

safetyglassesshouldbewornwhenmixingtheveterinarymedicinal

product.

-Inthecaseofaccidentalspillageontoskin,theaffectedareashould

bewashedimmediatelywithsoapandwater.

-Incaseofaccidentaleyecontact,irrigatetheeyesthoroughlywith

cleanrunningwaterimmediately.Seekmedicaladviceifirritation

persists.

-Contaminatedclothingshouldberemovedandanysplashesonto

theskinshouldbewashedoffimmediately.Washhandsafteruse.

-Hypersensitivityreactions(skinrash,urticaria)couldoccur.People

withknownhypersensitivitytotheactivesubstanceshouldavoid

contactwiththeveterinarymedicinalproduct.

Revised:November2011

AN:01317/2011

Page4of8

4.6 Adversereactions

Feedintakemaydecreaseduetothetreatmentandthegastriculcersinduced

bythetreatment.

Intolerancestudiesulcershavebeenobservedinupto70%ofthetreated

animals.

Whereadministrationisperformedovera24hourperiod,nosevereulcerswere

identified.Inapunctuatedadministrationoftheproduct(maximal3hoursfor

administration),atleast12%ofsevereulcerswereidentified.Threedaysafter

thecessationofdosing,gastriculcersgenerallyrecover(withsomeresidual

scarring)orareintheprocessofrecovery/cicatrisation.

4.7 Useduringpregnancyandlactation

Gestation:Donotuseinpregnantanimals.

Lactation:Notapplicable.

4.8 Interactionswithothermedicamentsandotherformsofinteractions

InteractionsbetweenKetoprofenandthemostcommonlyusedantibioticshave

notbeeninvestigated.

Pre-treatmentwithotheranti-inflammatorysubstancesmayresultinadditionalor

increasedadverseeffects.DonotadministercorticosteroidsorotherNSAIDs

concurrentlyorwithin24hoursofeachother.Thetreatment-freeperiod,

however,shouldtakeintoaccountthepharmacologicalpropertiesofthe

productsusedpreviously.Ketopropig100mg/mlmustnotbeadministeredin

conjunctionwithotherNSAIDsorglucocorticosteroids.Gastrointestinaltract

ulcerationmaybeexacerbatedbycorticosteroidsinanimalsgivennon-steroidal

anti-inflammatorydrugs.Theconcomitantadministrationofactivesubstances

thatarehighlyplasmaproteinboundmaydemonstrateacompetitiveeffectwith

theketoprofenwiththepossibilityofconsequenttoxiceffectsduetotheunbound

fractionofthedrug.

Avoidcombiningwithanticoagulantdrugs,particularlycoumarinderivativessuch

aswarfarin.

4.9 Amounttobeadministeredandadministrationroute

Theveterinarymedicinalproductisadministeredbyoralroute,dilutedin

drinkingwater.Administrationovera24hourperiodisrecommended.

Medicatedwatershouldbetheonlywatersupplyduringtheperiodoftreatment.

Medicatedwatershouldberefreshedevery24hours.Theproductmaybeput

directlyintotheheadertankorintroducedviaawaterproportionerpump.Once

thetreatmentperiodhasfinished,thepigsshouldbegivenunmedicatedwater.

Therecommendeddailydoseis3mgofketoprofen/kgbodyweightequivalentto

0.03mlofKetoProPig10%OralSolutionperkgbodyweight.

Revised:November2011

AN:01317/2011

Page5of8

Durationoftreatment:1day.Basedontherisk-benefitassessmentofthe

veterinarianadditionaladministrationforanother1-2daysatthemostcanbe

considered;seealso4.4and4.6.

Thewaterintakeofthepigstobetreatedshouldbemeasuredbefore

calculatingthetotalamountofproducttobeadministeredeachday.

Thefollowingcalculationshouldbemadetodeterminethequantityof

KetoProPig100mg/mlOralSolutioninmltobeaddedtothedailyconsumption

ofdrinkingwater:

0.03mlKetoProPig100mg/ml/ Averagebodyweight

(kg)

kgbodyweight/day xoftheanimalstobe

treated =mlKetoProPig100mg/ml/

Averageamountofdrinkingwater/animal(l) lofdrinkingwater

Topreventoverdosing,pigsshouldbegroupedaccordingtobodyweightandan

averagebodyweightestimatedasaccuratelyaspossible.

4.10Overdose(symptoms,emergencyprocedure,antidotesifnecessary)

Overdoseupto3xtherecommendeddosecancauseGIulcers,proteinloss,

andkidneyandliverdamage.Earlysignsoftoxicityincludelossofappetiteand

depression.Incaseofoverdosage,symptomatictreatmentshouldbeinitiated.

4.11Withdrawalperiod

Meatandoffal:2days.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antiinflammatoryandantirheumaticproducts,

non-steroids

ATCvetcode:QM01AE03

5.1PharmacodynamicProperties

Ketoprofen,2-(phenyl3benzoyl)propionicacid,isanonsteroidalanti-

inflammatorydrugbelongingtothearylpropionicacidgroup.Ketoprofeninhibits

thebiosynthesisofPGE2andPGF2alphawithoutaffectingtheratioof

PGE2/PGF2alphaandthromboxanes.Althoughitisacyclooxygenaseinhibitor,

ketoprofenissaidtostabilizelysosomalmembranesandantagonizesthe

actionsofbradykinin.Ketoprofenpossessesanti-inflammatory,analgesicand

antipyreticactivity.

Revised:November2011

AN:01317/2011

Page6of8

Theanti-inflammatoryactivityisincreasedbyanenantiomerconversionfromthe

(R)tothe(S)form.Indeed,the(S)formisknowntosupportthemajoranti-

inflammatoryactivityofketoprofen.

5.2 PharmacokineticProperties

Afterasingleoraladministration,themeanC

observedwas10.1µg.mL -1 at

ameanTmaxof0.8h.

Themean±SDtotalAUCwas30.5µg.h.mL -1

.Themean

SDbioavailability

was93%.

Afterrepeatedoraladministrationofthesamedoseindrinkingwater,thekinetic

profilepresentsprincipally2differentphasesperadministrationday,clearly

relatedtotheday- nightcycle,whichinfluencedtheanimal’swaterconsumption.

Thefirstphase(first8hoursafterofferingtreatment)correspondedtothe

absorptionphaseoftheproduct.Consideringtherapidabsorptionphaseforthe

singleadministration,thelongerphaseobservedforrepeatedadministrationsis

duetotheadministrationroute:ketoprofenadministeredviadrinkingwateris

consumedbytheanimalssparselyduringtheday.Theeliminationphase

observedinthefollowinghoursisdirectlyrelatedtothelowdrinkingwater

consumptionbytheanimalsduringthenighttime.

Themean

SDobservedC

was1.9µg.mL -1

.TheT

fluctuatebetween5

and32hoursafterthebeginningofadministrations.

Afterabsorption,ketoprofenbindsextensivelytoplasmaproteins,mainly

albumina,provingthatthisunionisenantioselective.Meandistributionvolume

was223.2mL/kg.

Thepredominantmetabolicrouteisbyglucoconjugation,formingthe

correspondingketoprofenmetabolites(50-80%oftheparentdrug),whichare

rapidlyexcretedthroughurine.Liveristhemainorganinvolvedintheelimination

ofthedrug.Meaneliminationlifetimevaluewas2.1hoursandMRT3.1hours.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Benzylalcohol

Argininebase

CitricAcidMonohydrate

PurifiedWater

6.2 Incompatibilities

Noneknown.

Revised:November2011

AN:01317/2011

Page7of8

6.3 Shelf-life

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:36months

Shelf-lifeafterfirstopeningtheimmediatepackaging:4months

Shelf-lifeafterdilution:24hours

6.4 Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorage

conditions

6.5 Natureandcompositionofimmediatepackaging

1litrewhiteHDPEcontainerscoatedwithfluorinatedpolymers,providedwith

whitepolypropylenecapswithscrewtopandsealedwithathreelayer-seal.

Eachcontainerisprovidedwithapolypropylenecupmeasuringdevice

graduatedfrom10upto75ml.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

LabianaLifeSciencesS.A.U.

C/Venus26

CanParelladaIndustrial

Terrassa

08228Barcelona

Spain

8. MARKETINGAUTHORISATIONNUMBER

Vm 32112/4000

9. DATEOFTHEFIRSTAUTHORISATION/RENEWALOFTHE

AUTHORISATION

Date:16July2008

10.DATEOFREVISIONOFTHETEXT

Date:November2011

Revised:November2011

AN:01317/2011

Page8of8

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

27-11-2018

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

Published on: Mon, 26 Nov 2018 Abstract In response to the EFSA call New approaches in identifying and characterizing microbial and chemical hazards, the project INNUENDO (https://sites.google.com/site/theinnuendoproject/) aimed to design an analytical platform and standard procedures for the use of whole‐genome sequencing in surveillance and outbreak investigation of food‐borne pathogens. The project firstly attempted to identify existing flaws and needs, and then to provide applicable cross‐sectorial ...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The product Bergazym® P100 contains a xylanase which is produced by a non‐genetically modified strain of Trichoderma reesei. The additive is available in a coated granular form and it is intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens for fattening, and weaned piglets at the dose of 1,500 EPU/kg feed. The production strain and the additive were fully characterised in a previous assessment of the Panel o...

Europe - EFSA - European Food Safety Authority Publications

24-10-2018

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Published on: Tue, 23 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for sows in order to have benefit in piglets. The additive HOSTAZYM® X contains endo‐1,4‐beta‐xylanase and is available in liquid and solid formulations. This product is authorised as a feed additive for chickens for fattening, tu...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

1-9-2018

Spodoptera frugiperda partial risk assessment

Spodoptera frugiperda partial risk assessment

Published on: Fri, 31 Aug 2018 00:00:00 +0200 EFSA was asked for a partial risk assessment of Spodoptera frugiperda for the territory of the EU focussing on the main pathways for entry, factors affecting establishment, risk reduction options and pest management. As a polyphagous pest, five commodity pathways were examined in detail. Aggregating across these and other pathways, we estimate that tens of thousands to over a million individual larvae could enter the EU annually on host commodities. Instigat...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 10 Aug 2018 00:00:00 +0200 This scientific opinion of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) deals with the safety evaluation of the recycling process General Plastic (EU register No RECYC153), which is based on the Starlinger Decon technology. The decontamination efficiency of the process was demonstrated by a challenge test. The input of this process is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes orig...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

25-6-2018

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

FDA approved Epidiolex (cannabidiol) oral solution, the first drug comprised of an active ingredient derived from marijuana, to treat two rare and severe forms of epilepsy.

FDA - U.S. Food and Drug Administration

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

There are no news related to this product.